Clinical research company George Clinical said on Thursday that it is working with Saint Luke's Mid America Heart Institute on a new study to explore whether SGLT inhibitor dapagliflozin can prevent disease progression in patients hospitalized with COVID-19 and at high risk for complications due to pre-existing cardio metabolic risk factors.
The global 'DARE-19' study will include 900 patients with approximately half of those coming from the United States and the remainder from other countries with high prevalence of COVID-19.
Study enrolment has started in the Kansas City metropolitan area at Saint Luke's Hospital of Kansas City and other other hospitals around the US.
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
Amgen offers Repatha through AmgenNow direct-to-patient programme
MedHub-AI's AutocathFFR receives national reimbursement approval in Japan
Early, Evidence-Led Cardiovascular Care Strengthened in High-Risk MENA Regions
Corstasis and U.S. Heart and Vascular partner to advance heart failure care with ENBUMYST
Eli Lilly and Company's orforglipron outperforms oral semaglutide in Phase 3 ACHIEVE-3 trial
Merck reports positive Phase 3 results for oral PCSK9 inhibitor enlicitide
Abbott's Navitor TAVI system granted CE Mark for expanded indication
Cereno Scientific receives FDA Fast Track designation for CS1 in pulmonary arterial hypertension
FDA lifts clinical hold on Rocket Pharmaceuticals' RP-A501 Phase 2 Danon disease trial
OptiBiotix signs distribution deal with major weight management company
Novartis to present cardiovascular abstracts portfolio data at ESC Congress in Madrid
LivaNova announces commercial launch of Essenz Perfusion System in China